Research Article

Clinical Efficacy of Fuzheng Guben Anticancer Decoction Combined with Taxol in Treating Ovarian Carcinoma and Its Effect on Complication Incidence

Table 2

Between-group comparison of T-cell subset levels ( ± s).

T-cell subsetControlExperimentalt/P

CD3+ (%)Before treatment46.55 ± 5.5446.76 ± 5.60
After treatment52.03 ± 5.8457.81 ± 6.024.359/<0.001

CD4+ (%)Before treatment32.74 ± 4.8232.86 ± 4.85
After treatment37.13 ± 4.3041.60 ± 4.764.407/<0.001

CD8+ (%)Before treatment32.60 ± 3.2932.44 ± 3.18
After treatment33.82 ± 3.1933.86 ± 3.210.056/0.956

CD4+/CD8+Before treatment1.03 ± 0.031.04 ± 0.04
After treatment1.10 ± 0.051.25 ± 0.0513.416/<0.001

indicated in the comparison of patients in the same group before and after treatment.